(Q48015505)

7 February 2018

title

Development of an abbreviated schizophrenia quality of life scale using a new method (English)

1 reference

7 February 2018

0 references

1 reference

6

1 reference

7 February 2018

Raquel E Gur

7

Raquel E Gur

1 reference

7 February 2018

5

Ruben C Gur

1 reference

7 February 2018

Warren B Bilker

1

Warren B Bilker

1 reference

7 February 2018

Colleen M Brensinger

2

Colleen Brensinger

1 reference

7 February 2018

Matthew M Kurtz

3

Matthew M Kurtz

1 reference

7 February 2018

author name string

Christian Kohler

4

1 reference

7 February 2018

language of work or name

English

0 references

publication date

17 October 2002

1 reference

7 February 2018

published in

Neuropsychopharmacology

1 reference

7 February 2018

volume

28

1 reference

7 February 2018

issue

4

1 reference

7 February 2018

page(s)

773-777

1 reference

7 February 2018

https://scigraph.springernature.com/pub.10.1038/sj.npp.1300093

exact match

0 references

cites work

Predicting quality of life from symptomatology in schizophrenia at exacerbation and stabilization.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300093

The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300093

Detecting improvement in quality of life and symptomatology in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300093

Quality of life in schizophrenia: a comparison of instruments. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300093

What are the functional consequences of neurocognitive deficits in schizophrenia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300093

Relations among clinical scales in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300093

Olanzapine versus placebo and haloperidol: quality of life and efficacy results of the North American double-blind trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300093

A separate disease within the syndrome of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300093

Effectiveness of attention training in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300093

A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300093

Intraclass correlations: uses in assessing rater reliability

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300093

A five-year followup study of deficit and nondeficit schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300093

The effects of neurocognitive remediation on executive processing in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300093

The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300093

inferred from DOI database lookup

7 January 2021

based on heuristic

Phenomenology and functioning in first-episode schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300093

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/SJ.NPP.1300093

1 reference

7 February 2018

Dimensions Publication ID

1053063238

0 references

Fatcat ID

release_be3ivrazhnggtmwlrku6zlrq6q

0 references

1 reference

7 February 2018